State coverage
Connecticut Medicaid and GLP-1 coverage
Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Gated the GLP-1s to diabetes, then added two cheap oral weight-loss drugs on the same day.
- Appeal deadline
- 60 days from the decision, and it has to be mailed — the statute counts from when the decision was made, not from when you opened the envelope source
- Date read
- September 2026
Connecticut is usually listed among the states that pulled back on these drugs. What its own bulletins show is a swap rather than a retreat.
In December 2024 the state started requiring a type 2 diabetes diagnosis code on the pharmacy claim for the older GLP-1s — Ozempic, Mounjaro, Trulicity and the rest. If your prescriber was using one of them for weight, the claim stopped paying. That is the part that got reported.
The part that did not: on the same bulletin that extended the transition period, Connecticut added coverage of two weight-loss drugs it had never paid for. Orlistat and phentermine became covered for HUSKY A, B, C and D from July 1, 2025. They are the old, cheap, oral ones rather than the injectables, but they are covered for weight loss itself, which is more than most states on this site will do.
Alongside that, the state opened three named doors to the newer drugs for reasons other than obesity, each in its own dated bulletin. And underneath all of it sits a provider manual that still says the program does not pay for obesity drugs at all — a sentence the 2025 bulletins have overtaken.
What we could verify for Connecticut
The tightening came first, and it works at the pharmacy counter rather than through a prior authorization. From December 15, 2024, "all new prescriptions for GLP-1 agonist medications will require a valid ICD-10 diagnosis code indicating Type 2 diabetes to be submitted in field 424-DO on the NCPDP D.0. pharmacy claim." The bulletin names them: "Trulicity, Byetta, Bydureon, Rybelsus, Victoza/liraglutide, Ozempic, and Mounjaro (combination GIP and GLP-1)". Members already on one for another reason were given a transition period rather than an immediate stop.
Connecticut Medical Assistance Program, Provider Bulletin 2024-66, Policy Transmittal 2024-30, effective December 2024 · source
The same bulletin that extended that transition also opened a door nobody reported. Its subject line reads "Updated Diagnosis Requirement for GLP-1 Agonist Medications and New Coverage of FDA Approved Weight Loss Drug Phentermine and Orlistat", and the text is explicit: "Effective 7/1/2025, the Department of Social Service (DSS) will cover two FDA approved oral medications for weight loss through the pharmacy benefit for HUSKY A, B, C, and D" — orlistat and phentermine. Claims for members already on a GLP-1 for a non-diabetes reason were extended "through July 31, 2025."
Connecticut Medical Assistance Program, Provider Bulletin 2025-31, Policy Transmittal 2025-12, effective June 2025 · source
Wegovy got a cardiovascular door in early 2025: "Effective February 3, 2025, the Department will reimburse for new prescriptions for Wegovy through the pharmacy benefit when prescribed to reduce the risk of Major Adverse Cardiac Event (MACE) in adults 18 and older with established cardiovascular disease and either obesity or overweight", across HUSKY A, B, C and D. The bulletin warns that "Any PA form submitted without the required information will be denied."
Connecticut Medical Assistance Program, Provider Bulletin 2025-04, effective February 2025 · source
Zepbound got a sleep apnea door six months later: "Effective July 1, 2025, the Department will reimburse for new prescriptions for Zepbound through the pharmacy benefit when prescribed for the treatment of obstructive sleep apnea in adults 18 and older", again across HUSKY A, B, C and D.
Connecticut Medical Assistance Program, Provider Bulletin 2025-32, effective June 2025 · source
A liver door followed in the autumn, and it narrows the drug it opens. "Effective November 3, 2025, the Department will reimburse new prescriptions for Wegovy through the pharmacy benefit when prescribed to treat Metabolic-Associated Steatohepatitis (MASH) in adults 18 and older" — for HUSKY A, C and D, not B. The existing cardiovascular form stays available for people who already meet those criteria, and the same bulletin adds a diagnosis requirement for Wegovy.
Connecticut Medical Assistance Program, Provider Bulletin 2025-54, effective October 2025 · source
Connecticut's provider manual still says the opposite, and it is still the live document on the state's own portal. Chapter 7, under "III. Services Not Covered", lists what "The Department will not pay for" and item (b) is "Any drugs used in the treatment of obesity." Its cover is dated October 1, 2020 and its body pages carry a REVISED 05/01/03 stamp — so a reader who finds this chapter first will conclude the wrong thing about orlistat and phentermine, which the 2025 bulletin covers.
Connecticut Medical Assistance Program, Provider Manual Chapter 7 — Pharmacy Services Regulation/Policy, effective October 2020 · source
The filing window is in statute rather than in a bulletin, and it is measured from the decision: an application for a fair hearing "shall be mailed to the commissioner within sixty days after the rendition of such decision." The same section requires the commissioner to hold the hearing "within thirty days from receipt" of the application. The chapter is revised to January 1, 2026.
Connecticut General Statutes §17b-60, Fair hearings by commissioner, effective January 2026 · source
Connecticut is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Connecticut Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Connecticut with the rest in the coverage matrix.
If you work for the State of Connecticut
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: State of Connecticut Health Plan (Office of the State Comptroller). Its pharmacy benefit runs through CVS Caremark.
Covered only through FlyteHealth program ($12.50/mo)
Connecticut's state plan covers weight loss drugs only when FlyteHealth (or Connecticut Children's weight program) prescribes them. You need a BMI of 30, or 27 with a weight-related condition, and you pay a $12.50 monthly program fee plus your normal Caremark copay.
"Medications prescribed for weight loss or weight management are covered by the plan ONLY if they are prescribed through FlyteHealth" or Connecticut Children's Weight Management providers.
Office of the State Comptroller, Care Compass, Medical Weight Management · source
"You can join if you have a of BMI of 30 or higher." "You can also join if you have a BMI of 27 or higher and have a weight-related health condition like diabetes, sleep apnea, heart disease, or liver disease."
Office of the State Comptroller, Care Compass, Medical Weight Management · source
"To participate, there is a ... required $12.50 monthly program fee. You will also be responsible ... for the cost of any prescriptions, which will be billed according to ... your existing CVS/Caremark coverage ... and standard tier structure." "Participants who do not complete the required ... activities will pay $25 per month."
Office of the State Comptroller, Care Compass, FlyteHealth FAQs, effective May 2026 · source
"Flyte was implemented in July 2023. Based on enrollment data through June 2025, 11,567 members have enrolled in Flyte since inception."
The Segal Group for the State of Connecticut, FlyteHealth Program Evaluation (published by the Office of the State Comptroller), effective March 2026 · source
"Prescription benefits are the same across all medical plans. There is a 4-tier copay structure." If a non-preferred brand is medically necessary, your doctor must "fax it to CVS Caremark".
Office of the State Comptroller, Care Compass, State Employee Pharmacy · source
If the appeal fails, or you cannot wait
Connecticut Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerRxSpan MDCheck availability | Multi-category telehealth that promises transparent pricing, then publishes no GLP-1 price on the page our link opens. |
| PartnerSnagRxCheck availability | Compounded semaglutide at $69 a month and tirzepatide at $119, the same at every dose, with no membership. Both are countdown sale prices, marked down from $299 and $399. Not available in Louisiana. |
| PartnerSkinnyRxCheck availability | Compounded semaglutide and tirzepatide injections at $99 for the first month, tablets at $149 and $199. No second-month price is printed for any of them. |
| PartneryourEraCheck availability | Compounded semaglutide at $79.20 a month and tirzepatide at $159.20. Both are six-month-plan prices, and the plan carries a six-month commitment. |
| PartnerbmiMDCheck availability | Compounded semaglutide from $119 a month and tirzepatide from $179. Both are limited-time sale prices, marked down from $228.60 and $349.20. |
| PartnerCollectiveCheck availability | Compounded semaglutide at $59 a month and tirzepatide at $69 at every dose, plus a required $199 yearly membership. It's free for 21 days, then billed for the full year at once, and it isn't refundable. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Connecticut Medical Assistance Program, Provider Bulletin 2024-66, Policy Transmittal 2024-30, effective December 2024 — Open the document
- Connecticut Medical Assistance Program, Provider Bulletin 2025-31, Policy Transmittal 2025-12, effective June 2025 — Open the document
- Connecticut Medical Assistance Program, Provider Bulletin 2025-04, effective February 2025 — Open the document
- Connecticut Medical Assistance Program, Provider Bulletin 2025-32, effective June 2025 — Open the document
- Connecticut Medical Assistance Program, Provider Bulletin 2025-54, effective October 2025 — Open the document
- Connecticut Medical Assistance Program, Provider Manual Chapter 7 — Pharmacy Services Regulation/Policy, effective October 2020 — Open the document
- Connecticut General Statutes §17b-60, Fair hearings by commissioner, effective January 2026 — www.cga.ct.gov/current/pub/chap_319q.htm